[Long-term disease stabilization by Strontium 89 (89Sr) for castration and docetaxel-resistant prostate cancer : a case report].
A 67-year old man was diagnosed with advanced prostate cancer with multiple pelvic lymph nodes and multiple bone metastases (cT2N1M1b), with an initial prostate specific antigen of 1,300 ng/ml. Prostate biopsy specimens revealed poorly differentiated adenocarcinoma, Gleason's score 5＋3. He was treated with maximal androgen blockade (MAB) from 2001, but showed resistance to hormone therapy and docetaxel in 2007. External radiation therapy for bone pain was difficult due to multiple lesions. 89Sr therapy was started in 2009. The therapy could be performed 5 times without any side effects. Good pain control and decreasing PSA was obtained at each dose.
The Department of Urology, Nishi-Kobe Medical Center, Japan.
Yuki
Y
Kamiyama
Ryo
R
Iguchi
Yuki
Y
Makino
Sojun
S
Kanamaru
Noriyuki
N
Ito
Kazufumi
K
Imanaka
D000230:Adenocarcinoma / Q000532:radiotherapy* / Q000628:therapy; D000368:Aged; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000532:radiotherapy* / Q000628:therapy; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D043823:Taxoids / Q000627:therapeutic use
D013326:Strontium Radioisotopes; D043823:Taxoids; D000077143:Docetaxel